title: Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.
abstract: The MUC1 C-terminal transmembrane subunit (MUC1-C) oncoprotein is a direct activator of the canonical nuclear factor-kappaB (NF-kappaB) RelA/p65 pathway and is aberrantly expressed in human multiple myeloma cells. However, it is not known whether multiple myeloma cells are sensitive to the disruption of MUC1-C function for survival. The present studies demonstrate that peptide inhibitors of MUC1-C oligomerization block growth of human multiple myeloma cells in vitro. Inhibition of MUC1-C function also blocked the interaction between MUC1-C and NF-kappaB p65 and activation of the NF-kappaB pathway. In addition, inhibition of MUC1-C in multiple myeloma cells was associated with activation of the intrinsic apoptotic pathway and induction of late apoptosis/necrosis. Primary multiple myeloma cells, but not normal B-cells, were also sensitive to MUC1-C inhibition. Significantly, treatment of established U266 multiple myeloma xenografts growing in nude mice with a lead candidate MUC1-C inhibitor resulted in complete tumor regression and lack of recurrence. These findings indicate that multiple myeloma cells are dependent on intact MUC1-C function for constitutive activation of the canonical NF-kappaB pathway and for their growth and survival.
authors.affiliation: Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115-6084, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Yin
authors.forename: Rehan
authors.initials: R
authors.lastname: Ahmad
authors.forename: Michio
authors.initials: M
authors.lastname: Kosugi
authors.forename: Turner
authors.initials: T
authors.lastname: Kufe
authors.forename: Baldev
authors.initials: B
authors.lastname: Vasir
authors.forename: David
authors.initials: D
authors.lastname: Avigan
authors.forename: Surender
authors.initials: S
authors.lastname: Kharbanda
authors.forename: Donald
authors.initials: D
authors.lastname: Kufe
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000502:physiology*; D047369:Chromatin Immunoprecipitation; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008969:Molecular Sequence Data; D018396:Mucin-1 / Q000737:chemistry / Q000502:physiology*; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D016328:NF-kappa B / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D014183:Transplantation, Heterologous
chemical_list: D018396:Mucin-1; D016328:NF-kappa B; D017382:Reactive Oxygen Species
references.citation: Nat Rev Cancer. 2009 Dec;9(12):874-85
references.pmid: 19935676
references.citation: Histol Histopathol. 2007 Aug;22(8):889-93
references.pmid: 17503346
references.citation: J Clin Invest. 2005 Oct;115(10):2625-32
references.pmid: 16200195
references.citation: Cancer Cell. 2004 Feb;5(2):163-75
references.pmid: 14998492
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5887-94
references.pmid: 17020997
references.citation: Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080
references.pmid: 18451130
references.citation: Blood. 1996 Feb 1;87(3):1104-12
references.pmid: 8562936
references.citation: Nat Immunol. 2002 Mar;3(3):221-7
references.pmid: 11875461
references.citation: Leuk Res. 2001 Mar;25(3):221-5
references.pmid: 11226518
references.citation: Br J Haematol. 2005 Jun;129(5):687-700
references.pmid: 15916692
references.citation: Clin Cancer Res. 1999 Oct;5(10 Suppl):3065s-3072s
references.pmid: 10541345
references.citation: Oncogene. 2006 Oct 30;25(51):6800-16
references.pmid: 17072329
references.citation: J Immunol. 1994 Sep 1;153(5):2102-9
references.pmid: 8051415
references.citation: Cell. 2008 Feb 8;132(3):344-62
references.pmid: 18267068
references.citation: J Immunol. 1997 May 15;158(10):4750-7
references.pmid: 9144489
references.citation: Mol Cancer Ther. 2009 Nov;8(11):3056-65
references.pmid: 19887552
references.citation: Blood. 1999 Feb 15;93(4):1287-98
references.pmid: 9949172
references.citation: Int J Oncol. 2009 Jun;34(6):1691-9
references.pmid: 19424588
references.citation: Cancer Cell. 2007 Aug;12(2):131-44
references.pmid: 17692805
references.citation: Nat Cell Biol. 2007 Dec;9(12):1419-27
references.pmid: 18037881
references.citation: Blood. 2009 May 21;113(21):5228-36
references.pmid: 19270264
references.citation: Br J Haematol. 2006 Nov;135(4):513-6
references.pmid: 17010104
references.citation: J Biol Chem. 2007 Jul 6;282(27):19321-30
references.pmid: 17500061
references.citation: Cancer Res. 2005 Nov 15;65(22):10413-22
references.pmid: 16288032
references.citation: J Immunol. 2005 Mar 1;174(5):2619-26
references.pmid: 15728468
references.citation: J Biol Chem. 2003 Sep 12;278(37):35458-64
references.pmid: 12826677
references.citation: J Biol Chem. 2007 Jan 5;282(1):257-66
references.pmid: 17102128
references.citation: Cancer Biol Ther. 2003 Mar-Apr;2(2):187-93
references.pmid: 12750561
references.citation: Methods Cell Biol. 1995;46:153-85
references.pmid: 7541883
references.citation: J Biol Chem. 2002 May 10;277(19):16639-47
references.pmid: 11872748
references.citation: Cancer Res. 2009 Sep 1;69(17):7013-21
references.pmid: 19706766
references.citation: Oncogene. 2001 Jul 27;20(33):4519-27
references.pmid: 11494147
references.citation: Mol Cell. 2007 Sep 21;27(6):992-1004
references.pmid: 17889671
references.citation: Br J Haematol. 2007 Jul;138(2):160-8
references.pmid: 17542984
references.citation: Int J Oncol. 2008 Jul;33(1):153-9
references.pmid: 18575761
references.citation: Cancer Res. 2009 Jun 15;69(12):5133-41
references.pmid: 19491255
references.citation: Cancer Cell. 2007 Aug;12(2):115-30
references.pmid: 17692804